Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So that would make 3-71 worth at least $14 billion not including the rest of the drug pipeline. Apples for Apples with Karuna's drug. Correct?
China limits short-selling in latest effort to stem a stock market rout
https://www.msn.com/en-us/money/markets/china-limits-short-selling-in-latest-effort-to-stem-a-stock-market-rout/ar-BB1hprXH
Saturday Night Special...
Aretha Franklin & George Michael - I Knew You Were Waiting (For Me) [Official Video] - A2-73
https://www.bing.com/videos/riverview/relatedvideo?q=Top%20hits%20of%20the%2080s%20youtube&mid=CC92CD2F7936A576B1D0CC92CD2F7936A576B1D0&ajaxhist=0
11 post by Investor before market open today. Working hard to keep the price down.
Nobody can really put an exact timeline on a drug progression and approval. It's all an approximate guess in good faith. I think Missling really tried to address timelines to the best of his current knowledge to let the share holders and market know. But in many cases drug trial information results were late from what he was told it would be. imo - It took Merck 1.3 years to report their Alzheimer's drug trial results.
Good question. Would need to research further..
"Revenue decreased 10% sequentially and 13% from the same quarter a year ago. During the quarter, we experienced increasing weakness across industrial and a sequential decline in automotive."
Perhaps the smart money sees continued increasing weakness across industrial and a sequential decline in automotive." The economy is not as good as the media claims. Further weakness in TI sector possible.
Short notice -
China’s Biggest Broker Curbs Short Sales After Stock Rout
"China Securities Co. will ban clients from using margin loans to buy and return stocks they sold short effective from Jan. 22, closing a popular channel for short sales, according to a notice sent to investors on Friday".
https://finance.yahoo.com/news/china-biggest-brokerage-restricts-short-025632255.html
China’s Biggest Broker Curbs Short Sales After Stock Rout
"China Securities Co. will ban clients from using margin loans to buy and return stocks they sold short effective from Jan. 22, closing a popular channel for short sales, according to a notice sent to investors on Friday".
https://finance.yahoo.com/news/china-biggest-brokerage-restricts-short-025632255.html
This stock has been manipulated down at every potential run up for eight years. Every time. It has a very unfair market cap valuation compared to other company's in the CNS biotech space.
The Electric-Vehicle Cheating Scandal
EV infrastructure needs another 50 to 75 years to match today's gas vehicle.
https://www.wsj.com/articles/the-electric-car-cheating-scandal-subsidy-rule-efficiency-falsehood-2798b4ab
Thank God for natural gas HEAT. Minus -5 deg. outside. 🙏
A2-73 still the best drug in the CNS space with a far better safety profile than any other drug. Approve it for Rett Syndrome as the new SOC.
Would somebody please turn on the solar panel heat! Thank you
Isn't grasshopper observer owned by Biogen?
"It will take an approval for an indication to realize that valuation. Once there is an approval that buyout indicates what 2-73 may be worth."
T - That company that Dr. Missling referenced was sold for $14 billion. Did they have a drug approved in the CNS space or no? Do they have a pipeline of other drugs? TIA
"why mention other company M&A humm maybe he wanted to hint the shareholder that he working on the partnership deal".
I agree. Dr. Missling is ultra conservative. Why even mention that? I don't think he would mention that if there wasn't something behind it.
What is that about $190.00 a share?
Possibly overrun by illegal alien's.
The Steep Climb Ahead For Cassava Sciences' Alzheimer's Drug
Investment Recommendation: "Strong Sell" due to high risks in simufilam's development and a valuation that doesn't align with its bleak clinical prospects.
https://seekingalpha.com/article/4661845-the-steep-climb-ahead-for-cassava-sciences-alzheimers-drug?mailingid=33946122&messageid=must_reads&serial=33946122.1683472&utm_campaign=Must%2BReads%2Brecurring%2B2024-01-09&utm_content=seeking_alpha&utm_medium=email&utm_source=seeking_alpha&utm_term=must_reads
Great news. The patent claims protect use of ANAVEX®2-73 (blarcamesine) to address a range of symptoms exhibited by patients suffering from neurodevelopmental and neurological conditions related to McCP2, such as abnormal breathing, abnormal cardiac function, abnormal feeding, abnormal choking, weight gain failure, abnormal sleep, seizures, abnormal gadolinium-enhancing lesions. Such conditions are frequently associated with diseases such as Rett syndrome, autism spectrum disorder, multiple sclerosis, cerebral palsy, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, Smith-Magenis syndrome, non-syndromic mental retardation, idiopathic neonatal encephalopathy, and idiopathic cerebral palsy. This newest patent is expected to remain in force at least until January 2037, not including any patent term extension.
I believe this new patent is worth $7 to $10 billion for A2-73 ( Blarcamazine ) imo.
I agree. AVXL is attacked by collusive shorts every time the company posts or presents. Every time. The stock is also attacked every time it's ready to make a breakout move. Every time for the past eight years.
Right. Lol. Pretty tough to survive in this environment if your an honest person.
A2-73 is the safest drug with efficacy in the CNS space. This drug alone without the rest of the drug line should be worth close to $15 billion if sold separately from the rest of the company. imo The safety of A2-73 in all drug trial results are best in class. imo
Nice find, Xena. Here it is. RWE with 2-73 making progress in the Rett Syndrome world. Nice...
Right on! Nice find, Xena. Thanks for posting..
FDA nods for innovative therapies containing an active ingredient or molecule not previously approved, rose to 55 in 2023, up from 37 in 2022 and 51 in 2021.
https://finance.yahoo.com/news/us-fda-approvals-bounce-back-182915592.html
A2-73 still the best drug in the CNS space with a far better safety profile than any other drug. Approve it for Rett Syndrome as the new SOC.
Interview the care givers. Show film footage of patients before and after drug trial. Post it on the web site
A2-73 is better than the current SOC.
"You can bet that all the powers-that-be will do what they can to foil Anavex."
Great post Hoskuld. You can see that clearly just by the paid company bashers here 24/7. It is actually reinforcing to see this and the desperation that goes with it.
This company has never missed on drug trial results and has proven that people get better by taking 2-73 if taken early enough in the disease.
"Yes, 3 positive testimonials are powerful endorsements for A2-73. Naysayers and shorty's may be in a heap of trouble in the very near term!"
Yes. Let's hear from more of the people taking 2-73 and their care takers. Let's show before and after video interviews of the patients prior to starting the drug and after.
Kentucky - Here's one reason. Lol
GLTU
"Isn't possible that some bashers are operating independently so they might buy a few more shares with their next paycheck?"
I doubt it. Their is a big effort to try and control this company since they are currently cash independent and they have the cutting edge drug line in the very lucrative CNS space. They are willing to spend a lot of money to hire people bashing the company and CEO / 24 hrs a day on this board. It's telling and another confirmation that their drug line is superior. Imo. It's all about control everywhere you look. GLTU
I think 90% of the shorting is by institutions that are accumulating. And I believe they hire/use many here on the board to ‘try’ to influence longs (so they can acquire more). The 18 mill shares short will be released (bought back) and will simply help fuel the profits of the shares these institutions already own.
Alzheimer's Disease Drug Development: Another Lost Year
Not sure if it was posted yet but Lane put out another article. I was not able to keep it open. Seeking Alpha
https://seekingalpha.com/article/4655976-alzheimers-disease-drug-development-another-lost-year?mailingid=33593483&messageid=must_reads&serial=33593483.1699267&utm_campaign=Must%2BReads%2Brecurring%2B2023-12-05&utm_content=seeking_alpha&utm_medium=email&utm_source=seeking_alpha&utm_term=must_reads
AVXL -2-73 We can be safer just for one day.
Wall Street Analysts See a 468.83% Upside in Anavex Life Sciences (AVXL): Can the Stock Really Move This High?
https://finance.yahoo.com/news/wall-street-analysts-see-468-145513955.html
Need to watch out for 2014. He will occasionally write a semi supporting comment to regain favor with longs but he is not an AVXL supporter. imo
Nice post bas. 101013 ABLE TO DO MUCH MORE HOUSEWORK THAN BEFORE is reason enough to approve 2-73. :)